An artist's impression of hookworm inside a human intestine. |
Trials of the vaccine candidate in mice, led by researchers at The University of Queensland, indicate that it is more than twice as effective than existing alternatives and marks a leap forward in the battle against the highly contagious parasite.
Professor Istvan Toth from UQ’s School of Chemistry and Molecular Biology said the ease with which the vaccine could be administered – via tablet, liquid or powder – would be a gamechanger for developing countries.
“Our vaccine candidate can be orally self-administered, bypassing the need for trained medical staff, and means there’s no requirement for special storage, enabling it to reach large, isolated populations,” Professor Toth said.
“Vaccination can be carried out at a significantly reduced cost, which not only improves the health of those affected and at high risk, but also helps improve economic growth in disease-endemic areas.”
Hookworm currently infects around half a billion people globally and lives within the human intestine, using the host’s blood as its source of nourishment, digested through a special set of enzymes.
It’s often found in regions with poor water quality, sanitation, and hygiene – greatly impacting on the physical and cognitive development of children and increasing the risk of mortality and miscarriage.